Latest Content

July Lung Cancer Highlights: Top 5 Updates Patients Should Know

July 30th 2025, 8:00pm

By Ryan Scott

Article

As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and patient-centered perspectives.

Jaypirca Shows Improvements Over Imbruvica in CLL/SLL

July 30th 2025, 7:00pm

By Spencer Feldman

Article

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

July Blood Cancer Highlights: Top 5 Updates Patients Should Know

July 30th 2025, 5:00pm

By Ryan Scott

Article

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, myelofibrosis, and CLL.

Building My Medical Team and Support System After a Cancer Diagnosis

July 30th 2025, 4:00pm

By Patti McGee

Article

After my cancer diagnosis, I built a strong medical team and support system that helped me heal; reaching out and accepting help made all the difference.

FDA Grants Orphan Drug Status to VT3989 for Mesothelioma Treatment

July 30th 2025, 3:00pm

By Spencer Feldman

Article

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s development.

Making Cancer Clinical Trials More Accessible in Local Communities

July 30th 2025, 1:00pm

By Kimberly Demirhan

Video

Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.

My Cancer Passion: Writing It Down

July 29th 2025, 9:00pm

By Debbie Legault

Article

When my daughter was diagnosed with breast cancer, writing our truth helped me and others face the harsh realities and lasting impact of cancer survivorship.

The Leukemia & Lymphoma Society Unveils Name Change to Reach All Blood Cancer Patients

July 29th 2025, 8:50pm

By The Leukemia & Lymphoma Society

Article

The Leukemia & Lymphoma Society, a nonprofit in funding blood cancer research, patient support and advocacy, is becoming Blood Cancer United on August 28.

Some Pediatric Cancer Treatments Tied to Faster Aging in Survivors

July 29th 2025, 8:00pm

By Dr. Zhaoming Wang

Video

Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.

July Prostate Cancer Highlights: Top 5 Updates Patients Should Know

July 29th 2025, 7:00pm

By Ryan Scott

Article

New insights highlight how prostate cancer is now managed as a chronic disease, with emerging treatments and real-world data offering renewed hope for patients.

True Life Stories About Cancer Can Inspire Others

July 29th 2025, 5:00pm

By Bonnie Annis

Article

Watching a true-life story about a woman’s battle with cancer has given me a new perspective on life.

July Breast Cancer Highlights: Top 5 Updates Patients Should Know

July 29th 2025, 4:00pm

By Ryan Scott

Article

July brought major breast cancer updates, and CURE is sharing the latest, as recent developments underscore how quickly the landscape continues to evolve.

FDA Grants Priority Review to Imfinzi for Early Gastric Cancers

July 29th 2025, 3:00pm

By Spencer Feldman

Article

Imfinzi plus chemo cut progression or death risk in early gastric cancer; the FDA's decision is expected late 2025 following breakthrough designation.

How Progress in Care is Affecting Patients With Lung Cancer

July 29th 2025, 1:00pm

By Dr. Jacob Sands

Video

Dr. Jacob Sands discusses progress in lung cancer treatment, as well as what patients should understand about how their care options may evolve over time.

Adverse Event Management and Treatment Response Assessment

July 29th 2025, 12:05pm

By Amrita Krishnan, MD

Video

Panelists discuss how patient portal use improves communication by allowing patients to report side effects with photos for accurate evaluation, and how treatment effectiveness is monitored through carefully timed blood tests, imaging, and bone marrow biopsies—including minimal residual disease testing—to balance thorough assessment with minimizing patient discomfort.